stockrowImmunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Revenue
- +69.8%
- EPS
- −30.0%
- Free cash flow
- −27.0%
Quarter to June 2026, against a year earlier
Follow IMNM
Alert me
Immunome, Inc. (IMNM) Shares outstanding
Immunome, Inc.'s shares outstanding at the end of fiscal 2025 was $87.4M, up 49.0% from $58.6M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $113.3M. Over the past ten years it has ranged from $1.1M (fiscal 2018) to $87.4M (fiscal 2025) — the current reading is the highest in ten years. Immunome, Inc. ranks 119th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $87.4M | 48.96% |
| FY2024 | $58.6M | 195.50% |
| FY2023 | $19.8M | 63.63% |
| FY2022 | $12.1M | 5.10% |
| FY2021 | $11.5M | 240.38% |
| FY2020 | $3.4M | 209.87% |
| FY2019 | $1.1M | 0.64% |
| FY2018 | $1.1M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $113.3M | 0.12% |
| Mar 2026 | $113.1M | 29.52% |
| Dec 2025 | $87.4M | (0.69%) |
| Sep 2025 | $88.0M | 1.09% |
| 23 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ADMA ADMA Biologics Inc compare | $225.8M |
| BHVN Biohaven Ltd. compare | $151.0M |
| AUPH Aurinia Pharmaceuticals Inc compare | $135.2M |
| IMNM Immunome, Inc. | $113.3M |
| CLDX Celldex Therapeutics, Inc. compare | $77.8M |
| VERA Vera Therapeutics, Inc. compare | $71.8M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $65.9M |
| VCEL Vericel Corporation compare | $53.0M |
| PVLA Palvella Therapeutics, Inc. compare | $14.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on IMNM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Altman Z-score
- The full statement